Zac Jiwa, a federal Medicare official, delivered a eulogy of sorts at a Thursday Medicare event highlighting the successes of ...
CAR-T therapy is toting up more remissions in autoimmune disease, and generating a flood of experimentation and investment.
The panel had become a flashpoint as RFK Jr.'s health department worked to limit the number of recommended childhood shots.
Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA?
In December, Trump said he would summon health insurance execs to the White House. It doesn't seem a meeting ever happened.
For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...
A smart contact lens described in a research paper on Wednesday combines therapeutic and diagnostic capabilities for glaucoma ...
MAHA ELEVATE could open a federal funding pipeline to interventions that can't survive contact with a plausibility filter.
FDA rejects a proposal to deregulate certain types of AI devices, pharma invests $50 million in DTx, and more.
Last month, a group of 12 Senate Democrats proposed a framework for rebuilding the health care system. The idea was to spur ...
Pharmalittle: We’re reading about top pharma lobbyist stepping down, genes and GLP-1 drugs, and more
Steve Ubl, chief executive of PhRMA, plans to step down at the end of the year, after more than a decade leading the main ...
Chatterjee is a professor of economic development, innovation, and global health economy at the University of Sussex and an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results